Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Wasmuth

Showing results (51-60 of 54) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 54 results.
Epidemiology and Infection|October 27, 2016
Measles, mumps, rubella and VZV: importance of serological testing of vaccine-preventable diseases in young adults living with HIV in GermanyC Schwarze-Zander, R Draenert, C Lehmann, et al.
AIDS (London, England)|December 11, 2023
Heavy antiretroviral exposure and exhausted/limited antiretroviral options: predictors and clinical outcomesAmanda Mocroft, Annegret Pelchen-Matthews, Jennifer Hoy, et al.
HIV Medicine|June 27, 2020
Treatment outcomes of integrase inhibitors, boosted protease inhibitors and nonnucleoside reverse transcriptase inhibitors in antiretroviral-naïve persons starting treatmentA Mocroft, B Neesgard, R Zangerle, et al.
Clinical and Experimental Immunology|April 24, 2013
The German national registry for primary immunodeficiencies (PID)B Gathmann, S Goldacker, M Klima, et al.
Pageof 6

Showing results (51-60 of 54) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 54 results.
Epidemiology and Infection|October 27, 2016
Measles, mumps, rubella and VZV: importance of serological testing of vaccine-preventable diseases in young adults living with HIV in GermanyC Schwarze-Zander, R Draenert, C Lehmann, et al.
AIDS (London, England)|December 11, 2023
Heavy antiretroviral exposure and exhausted/limited antiretroviral options: predictors and clinical outcomesAmanda Mocroft, Annegret Pelchen-Matthews, Jennifer Hoy, et al.
HIV Medicine|June 27, 2020
Treatment outcomes of integrase inhibitors, boosted protease inhibitors and nonnucleoside reverse transcriptase inhibitors in antiretroviral-naïve persons starting treatmentA Mocroft, B Neesgard, R Zangerle, et al.
Clinical and Experimental Immunology|April 24, 2013
The German national registry for primary immunodeficiencies (PID)B Gathmann, S Goldacker, M Klima, et al.
Pageof 6